VBS
Pharmaceuticals, Biotechnology & Life Sciences
Vectus Biosystems
- Short interest
- <0.01%
- as of 10 Nov 2025
- Reported shorts
- 1.1K
- Shares on issue
- 53.333M
Vectus Biosystems (VBS) company profile
Profile, insiders and operations
Company
AI-generated research profile of Vectus Biosystems
Pharmaceuticals
Biotechnology
Life Sciences
Anti-fibrotic drug
Medical Research
Vectus Biosystems is a medical research and development company focused on developing therapies for fibrosis and hypertension. Their lead drug candidate, VB0004, is undergoing Phase I human trials as an anti-fibrotic treatment. The company intends to remain a research and development entity, licensing its current and future technologies.
Who owns it
2 substantial holders disclosing 18.10%
Hedge fund 6.52%, Unclassified 11.58%
| Holder | Kind | Voting power | Change | As at | Notice |
|---|---|---|---|---|---|
| Kefford Holdings Pty Ltd ATF The Kefford Family Trust | Unclassified | 11.58% | +1.75 pp | 2026-05-27 | |
| Regal Partners Funds Management Pty Limited | Hedge fund | 6.52% | −1.91 pp | 2026-05-27 |
From ASX substantial holding notices (5% or more), index ETF holdings files and super fund portfolio holdings disclosures. Holders' interests can overlap. How ownership is read.
VBS intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Sign in to unlock the dossierFree account · no card required